The Lancet Global Health
-
1
[Comment] Converging global crises and the re-emergence of neglected tropical diseases: the case of noma
-
2
[Articles] Impact of two decades of humanitarian and development assistance and the projected mortality consequences of current defunding to 2030: retrospective evaluation and forecasting analysis
-
3
[Corrections] Correction to Lancet Glob Health 2023; 11: e1459–63
-
4
[Articles] The incidence and antimicrobial resistance of Shigella-attributable diarrhoea in young children in low-income and middle-income countries from the multicountry Enterics for Global Health (EFGH) Shigella Surveillance Study: a prospective, facili
-
5
[Corrections] Correction to Lancet Glob Health 2026; 14: e466–74
-
6
[Articles] Intravenous ferric carboxymaltose versus oral ferrous sulphate for the treatment of moderate-to-severe postpartum anaemia in Nigerian women (IVON-PP): an open-label, randomised controlled trial
-
7
[Articles] Effect on birthweight of an antenatal multiple micronutrient supplementation programme compared with iron–folic acid supplementation: a cluster-randomised, controlled trial in 85 698 Ethiopian women
-
8
[Comment] Diagnostic innovations to find the missing millions with tuberculosis
-
9
[Corrections] Correction to Lancet Glob Health 2026; published online March 11 https://doi.org/10.1016/S2214-109X(25)00534-0
-
10
[Comment] From commitment to action: why 2027 must mark the turning point for universal health coverage
The Lancet Haematology
-
1
[Clinical Picture] An otherwise smouldering multiple myeloma with a solitary osteolytic lesion and soft-tissue mass
-
2
[Review] Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignancies
-
3
[Editorial] Mental health at the heart of haematology
-
4
[Comment] Two decades of phase 1 and 2 trials in relapsed or refractory diffuse large B-cell lymphoma
-
5
[In Focus] Leveraging TikToks in clinical practice
-
6
[In Focus] From enrolment to authorship: racial and global disparities in phase 3 multiple myeloma clinical trials
-
7
[Articles] Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial
-
8
[Articles] Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis
-
9
[Articles] Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
-
10
[Articles] Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial
The Lancet Healthy Longevity
-
1
[Review] The crucial role of normative ageing in respiratory pathogenesis
-
2
[Editorial] Mobility as a pillar for healthy ageing
-
3
[Comment] Physical activity and biological ageing: the need for stronger causal evidence
-
4
[Articles] Physical activity and biological age measured by DNA methylation clocks: a systematic review and meta-analysis
-
5
[Comment] Air pollution, population ageing, and dementia burden in China
-
6
[Articles] Trends of PM2·5-attributable dementia deaths in the context of population ageing in China, 2000–60: a health impact assessment
-
7
[Comment] Walking limitation trajectories: a healthy longevity marker
-
8
[Articles] Life-course trajectories and modifiable risk factors for incident walking limitation and mortality in 25 high-income, middle-income, and low-income countries (PURE): a prospective cohort study
-
9
[Articles] Muscle failure and risk of adverse outcomes in older adults: a derivation and multicohort validation study
-
10
[Review] Effectiveness of interventions on cognitive decline risk for people living with HIV on antiretroviral therapy: a systematic review
The Lancet HIV
-
1
[Culture] Love, loss, and urban disillusionment in dystopian London
-
2
[Viewpoint] Cigarette smoking in PrEP recipients: a challenge and an opportunity
-
3
[Comment] Long-acting PrEP and equitable HIV prevention in Brazil
-
4
[Review] Histoplasmosis: a missing piece in the global efforts to end HIV deaths
-
5
[Feature] Crisis and resilience in the Pacific's HIV emergency
-
6
[Comment] Metabolic syndrome and cardiovascular risk on INSTIs
-
7
[Articles] Incident diabetes after switching to integrase strand transfer inhibitors in people with HIV in the USA and Canada: a cohort study
-
8
[Articles] Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE
-
9
[Articles] Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis
-
10
[Editorial] The intersection of HIV and non-communicable diseases
The Lancet Infectious Diseases
-
1
[Personal View] Future-proofing tuberculosis therapy: framework for concurrent drug and resistance testing development
-
2
[Review] British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases: 2025 update
-
3
[Review] Empirical and targeted antimicrobial therapy in patients with febrile neutropenia and haematological malignancy or after haematopoietic cell transplantation: recommendations from the 10th European Conference on Infections in Leukaemia
-
4
[Grand Round] Below-knee amputation following osteomyelitis from multidrug-resistant Stenotrophomonas maltophilia in a diabetic foot ulcer
-
5
[Articles] Safety and immunogenicity of a conjugate vaccine candidate against Salmonella enterica serovars Typhi and Paratyphi A in healthy adults in Europe: a phase 1 randomised controlled trial
-
6
[Articles] Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial
-
7
[Comment] Strength of ATLAS or lady luck in a sepsis management trial?
-
8
[Comment] Reimagining radical cure for Plasmodium vivax
-
9
[Articles] Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial
-
10
[Articles] Efficacy of ETVAX, a vaccine against enterotoxigenic Escherichia coli-positive diarrhoea in Gambian children: a double-blind, randomised, placebo-controlled, phase 2b trial
The Lancet Microbe
-
1
[Comment] The disparaging requirements of Article 5.5 of the IVDR for laboratories
-
2
[News] Spike in diphtheria in Africa raises concerns
-
3
[Correspondence] Cryptic diversity of coronaviruses in urban wastewater in central China
-
4
[Correspondence] Leveraging hybridisation capture sequencing to strengthen wastewater pathogen genomic surveillance
-
5
[Review] Global perspective on gaps in fungal diagnostics in low-resource settings: WHO landscape analysis and research priorities for invasive fungal diseases
-
6
[Personal View] Spillover of pseudorabies virus variants to humans: an urgent call for pseudorabies eradication in domestic pigs
-
7
[Comment] Pathogen access and benefit sharing in a pandemic: working towards fair exchange?
-
8
[Correspondence] Antimicrobial resistance in Helicobacter pylori: from mutation catalogues to clinical practice
-
9
[Correspondence] Drug-resistant fungi: the unintended consequence of modern immunosuppression
-
10
[Personal View] Research on the genome of microorganisms: ethical considerations and recommendations regarding the incidental bystander sequencing of human genetic material
The Lancet Neurology
-
1
[Articles] Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial
-
2
[Comment] A step towards disease-modifying therapy for multiple system atrophy
-
3
[Articles] Endovascular treatment for medium or distal vessel occlusion stroke (DISTAL): 12-month outcomes of a multicentre, open-label, randomised trial
-
4
[Articles] Identification of genetic modifiers of autosomal dominant Alzheimer's disease: a genome-wide association study
-
5
[Review] Diagnosis and pathogenesis of dystonia: clinical heterogeneity, shared mechanisms, and neurodevelopmental origins
-
6
[Editorial] The US Parkinson's disease community demands prevention
-
7
[Correspondence] Building systems-based epilepsy surgery in sub-Saharan Africa – Authors’ reply
-
8
[Articles] Safety, tolerability, and efficacy of acetazolamide in idiopathic normal pressure hydrocephalus (DRAIN) in Sweden: a randomised, double-blind, placebo-controlled, phase 2 trial
-
9
[Correspondence] Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis
-
10
[Correspondence] Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis
The Lancet Oncology
-
1
[News] Carcinogenicity of tris(chloropropyl) phosphate, butyraldehyde, and cumyl hydroperoxide
-
2
[News] US oil blockade pushes Cuba's health system into crisis
-
3
[News] US cancer vaccines research at “tipping point” as NCI backs $200 million initiative
-
4
[News] Senators demand explanation for US Preventive Services Task Force halt
-
5
[News] European Breast Cancer Conference 2026
-
6
[News] Canada's Yukon Territory publishes First Nations Cancer Strategy
-
7
[Articles] Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial
-
8
[News] UK MHRA–NICE pathway to create faster regulatory approval
-
9
[News] Trump's 2027 budget calls for further cuts to health research
-
10
[Articles] Estimating global cancer survival and mortality from 1990 to 2050: a simulation-based analysis of 17 cancers
The Lancet Planetary Health
-
1
[Newsdesk] Planetary Health Research Digest
-
2
[Personal View] Governing artificial intelligence for planetary health
-
3
[Personal View] Leave no one behind: a call to include people with disabilities in climate change and health research
-
4
[Comment] Framing climate change, migration, and health as a syndemic
-
5
[Comment] Rethinking labour in food systems for planetary health
-
6
[Articles] Region-specific solutions for clean cooking and heating in rural China: a cost–benefit analysis
-
7
[Viewpoint] Healthpunk: speculative methods for the future of planetary health
-
8
[Articles] Estimating the vulnerability contribution to 1990–2019 changes in the health burden of ambient air pollution: a global modelling study
-
9
[Personal View] Car dependency and US environmental health research: a long drive from motonormativity to planetary health
-
10
[Articles] Association between Great Salt Lake desiccation, air quality, and major depressive episodes: an ecological study